2
|
Mursalin MH, Coburn PS, Miller FC, Livingston ET, Astley R, Callegan MC. Innate Immune Interference Attenuates Inflammation In Bacillus Endophthalmitis. Invest Ophthalmol Vis Sci 2020; 61:17. [PMID: 33180117 PMCID: PMC7671874 DOI: 10.1167/iovs.61.13.17] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Accepted: 10/20/2020] [Indexed: 02/07/2023] Open
Abstract
Purpose To explore the consequences of innate interference on intraocular inflammatory responses during Bacillus endophthalmitis. Methods Bacillus endophthalmitis was induced in mice. Innate immune pathway activation was interfered by injecting S layer protein-deficient (∆slpA) B. thuringiensis or by treating wild-type (WT)-infected mice with a TLR2/4 inhibitor (WT+OxPAPC). At 10 hours postinfection, eyes were harvested and RNA was purified. A NanoString murine inflammation panel was used to compare gene expression in WT-infected, WT+OxPAPC, ∆slpA-infected, and uninfected eyes. Results In WT-infected eyes, 56% of genes were significantly upregulated compared to uninfected controls. Compared to WT-infected eyes, the expression of 27% and 50% of genes were significantly reduced in WT+OxPAPC and ∆slpA-infected eyes, respectively. Expression of 61 genes that were upregulated in WT-infected eyes was decreased in WT+OxPAPC and ∆slpA-infected eyes. Innate interference resulted in blunted expression of complement factors (C3, Cfb, and C6) and several innate pathway genes (TLRs 2, 4, 6, and 8, MyD88, Nod2, Nlrp3, NF-κB, STAT3, RelA, RelB, and Ptgs2). Innate interference also reduced the expression of several inflammatory cytokines (CSF2, CSF3, IL-6, IL-1β, IL-1α, TNFα, IL-23α, TGFβ1, and IL-12β) and chemokines (CCL2, CCL3, and CXCLs 1, 2, 3, 5, 9, and 10). All of the aforementioned genes were significantly upregulated in WT-infected eyes. Conclusions These results suggest that interfering with innate activation significantly reduced the intraocular inflammatory response in Bacillus endophthalmitis. This positive clinical outcome could be a strategy for anti-inflammatory therapy of an infection typically refractory to corticosteroid treatment.
Collapse
Affiliation(s)
- Md Huzzatul Mursalin
- Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Department of Ophthalmology, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
| | - Phillip S. Coburn
- Department of Ophthalmology, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
- Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
| | - Frederick C. Miller
- Department of Cell Biology and Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
| | - Erin T. Livingston
- Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
| | - Roger Astley
- Department of Ophthalmology, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
- Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
| | - Michelle C. Callegan
- Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Department of Ophthalmology, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
- Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
| |
Collapse
|
3
|
Chistyakov DV, Azbukina NV, Astakhova AA, Goriainov SV, Chistyakov VV, Tiulina VV, Baksheeva VE, Kotelin VI, Fedoseeva EV, Zamyatnin AA, Philippov PP, Kiseleva OA, Bessmertny AM, Senin II, Iomdina EN, Sergeeva MG, Zernii EY. Comparative lipidomic analysis of inflammatory mediators in the aqueous humor and tear fluid of humans and rabbits. Metabolomics 2020; 16:27. [PMID: 32052201 DOI: 10.1007/s11306-020-1650-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Accepted: 02/04/2020] [Indexed: 02/06/2023]
Abstract
INTRODUCTION Ocular inflammation is a key pathogenic factor in most blindness-causing visual disorders. It can manifest in the aqueous humor (AH) and tear fluid (TF) as alterations in polyunsaturated fatty acids (PUFAs) and their metabolites, oxylipins, lipid mediators, which are biosynthesized via enzymatic pathways involving lipoxygenase, cyclooxygenase or cytochrome P450 monooxygenase and specifically regulate inflammation and resolution pathways. OBJECTIVES This study aimed to establish the baseline patterns of PUFAs and oxylipins in AH and TF by their comprehensive lipidomic identification and profiling in humans in the absence of ocular inflammation and comparatively analyze these compounds in the eye liquids of rabbits, the species often employed in investigative ophthalmology. METHODS Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used for qualitative and quantitative characterization of lipid compounds in the analyzed samples. RESULTS A total of 28 lipid compounds were identified, including phospholipid derivatives and PUFAs, as well as 22 oxylipins. Whereas the PUFAs included arachidonic, docosahexaenoic and eicosapentaenoic acids, the oxylipins were derived mainly from arachidonic, linoleic and α-linolenic acids. Remarkably, although the concentration of oxylipins in AH was lower compared to TF, these liquids showed pronounced similarity in their lipid profiles, which additionally exhibited noticeable interspecies concordance. CONCLUSION The revealed correlations confirm the feasibility of rabbit models for investigating pathogenesis and trialing therapies of human eye disorders. The identified metabolite patterns suggest enzymatic mechanisms of oxylipin generation in AH and TF and might be used as a reference in ocular inflammation studies.
Collapse
Affiliation(s)
- Dmitry V Chistyakov
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, Moscow, Russia, 119992.
| | - Nadezhda V Azbukina
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, Moscow, Russia, 119992
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia, 119234
| | - Alina A Astakhova
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, Moscow, Russia, 119992
| | | | | | - Veronika V Tiulina
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, Moscow, Russia, 119992
| | - Viktoriia E Baksheeva
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, Moscow, Russia, 119992
| | - Vladislav I Kotelin
- Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia, 105062
| | - Elena V Fedoseeva
- Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia, 105062
| | - Andrey A Zamyatnin
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, Moscow, Russia, 119992
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russia, 119991
| | - Pavel P Philippov
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, Moscow, Russia, 119992
| | - Olga A Kiseleva
- Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia, 105062
| | | | - Ivan I Senin
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, Moscow, Russia, 119992
| | - Elena N Iomdina
- Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia, 105062
| | - Marina G Sergeeva
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, Moscow, Russia, 119992
| | - Evgeni Yu Zernii
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, Moscow, Russia, 119992.
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russia, 119991.
| |
Collapse
|
4
|
Chistyakov DV, Azbukina NV, Goriainov SV, Chistyakov VV, Gancharova OS, Tiulina VV, Baksheeva VE, Iomdina EN, Philippov PP, Sergeeva MG, Senin II, Zernii EY. [Inflammatory metabolites of arahidonic acid in tear fluid in UV-induced corneal damage]. BIOMEDIT︠S︡INSKAI︠A︡ KHIMII︠A︡ 2019; 65:33-40. [PMID: 30816095 DOI: 10.18097/pbmc20196501033] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The ultraviolet (UV) B-induced damage of the eye surface of experimental animals (rabbits) includes loss of corneal epithelium, apoptosis of keratocytes and stromal edema. These changes are accompanied by clinically and histologically manifested corneal inflammation, neutrophil infiltration, and exudation of the anterior chamber of the eye. According to mass spectrometric analysis, UV-induced corneal damage is associated with pronounced changes in the lipid composition of tears, including a decrease in the amount of arachidonic acid and prostaglandin E2 and an increase in the concentrations of prostaglandin D2 and its derivative 15d-PGJ2. In addition, it is accompanied by an alteration in the levels of hydroxyeicosate tetraenic acid derivatives, namely upregulation of 12-HETE and downregulation of 5-HETE. The revealed changes indicate the activation of metabolic pathways involving 5-lipoxygenase, 12-lipoxygenase, cyclooxygenase 1 and 2, and prostaglandin-D-synthase. These findings contribute to understanding mechanisms of UV-induced keratitis and point on feasibility of selective anti-inflammatory therapy for improving corneal regeneration after iatrogenic UV damage.
Collapse
Affiliation(s)
- D V Chistyakov
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
| | - N V Azbukina
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
| | - S V Goriainov
- Peoples` Friendship University of Russia, Moscow, Russia
| | - V V Chistyakov
- Peoples` Friendship University of Russia, Moscow, Russia
| | - O S Gancharova
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
| | - V V Tiulina
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
| | - V E Baksheeva
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
| | - E N Iomdina
- Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia
| | - P P Philippov
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
| | - M G Sergeeva
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
| | - I I Senin
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
| | - E Yu Zernii
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia; Sechenov First Moscow State Medical University, Institute of Molecular Medicine, Moscow, Russia
| |
Collapse
|
5
|
Villoslada P, Alonso C, Agirrezabal I, Kotelnikova E, Zubizarreta I, Pulido-Valdeolivas I, Saiz A, Comabella M, Montalban X, Villar L, Alvarez-Cermeño JC, Fernández O, Alvarez-Lafuente R, Arroyo R, Castro A. Metabolomic signatures associated with disease severity in multiple sclerosis. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2017; 4:e321. [PMID: 28180139 PMCID: PMC5278923 DOI: 10.1212/nxi.0000000000000321] [Citation(s) in RCA: 79] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Accepted: 12/19/2016] [Indexed: 12/20/2022]
Abstract
Objective: To identify differences in the metabolomic profile in the serum of patients with multiple sclerosis (MS) compared to controls and to identify biomarkers of disease severity. Methods: We studied 2 cohorts of patients with MS: a retrospective longitudinal cohort of 238 patients and 74 controls and a prospective cohort of 61 patients and 41 controls with serial serum samples. Patients were stratified into active or stable disease based on 2 years of prospective assessment accounting for presence of clinical relapses or changes in disability measured with the Expanded Disability Status Scale (EDSS). Metabolomic profiling (lipids and amino acids) was performed by ultra-high-performance liquid chromatography coupled to mass spectrometry in serum samples. Data analysis was performed using parametric methods, principal component analysis, and partial least square discriminant analysis for assessing the differences between cases and controls and for subgroups based on disease severity. Results: We identified metabolomics signatures with high accuracy for classifying patients vs controls as well as for classifying patients with medium to high disability (EDSS >3.0). Among them, sphingomyelin and lysophosphatidylethanolamine were the metabolites that showed a more robust pattern in the time series analysis for discriminating between patients and controls. Moreover, levels of hydrocortisone, glutamic acid, tryptophan, eicosapentaenoic acid, 13S-hydroxyoctadecadienoic acid, lysophosphatidylcholines, and lysophosphatidylethanolamines were associated with more severe disease (non-relapse-free or increase in EDSS). Conclusions: We identified metabolomic signatures composed of hormones, lipids, and amino acids associated with MS and with a more severe course.
Collapse
Affiliation(s)
- Pablo Villoslada
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Cristina Alonso
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Ion Agirrezabal
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Ekaterina Kotelnikova
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Irati Zubizarreta
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Irene Pulido-Valdeolivas
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Albert Saiz
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Manuel Comabella
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Xavier Montalban
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Luisa Villar
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Jose Carlos Alvarez-Cermeño
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Oscar Fernández
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Roberto Alvarez-Lafuente
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Rafael Arroyo
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| | - Azucena Castro
- Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain
| |
Collapse
|